论文部分内容阅读
近年来,急性淋巴细胞性白血病(以下简称急淋)的疗效已有显著提高.但长期存活率及治愈率仍较低。诱导缓解治疗是急淋治疗的第一步,治疗是否得当,与病人的预后有关。为了加深对初治急淋的认识及从中取得点滴经验,现将我科收治的102例初治急淋的诱导缓解治疗清况报告如下.
In recent years, the efficacy of acute lymphoblastic leukemia (hereinafter referred to as acute lymphoblastic) has been significantly improved, but long-term survival and cure rates are still low. Induced remission treatment is the first step of acute lymph node therapy, treatment is appropriate, and the patient’s prognosis. In order to deepen the understanding of acute lymphoblastic and get some dripping experience, now we receive the treatment of 102 cases of acute lymphoblastic response to treatment of fresh clear as follows.